Skip to main content

Cetuximab (Erbitux)

Cetuximab is used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer.

It is a chimeric monoclonal antibody that binds and inhibits the epidermal growth factor receptor (EGFR).

It is administered through intravenous infusion every week.

In 2016, it sold €350 million in Europe.

Labs that test for drug level:

University of Tours